‘Safer’ clot-buster right on the target usting ‘safer’ drug on target
The therapy works by fusing an existing anticoagulant, single-chain urokinase plasminogen activator, with an antibody specifically targeted to activated platelets that form part of the coagulation system. It specifically targets the area where the vessel is blocked, unlike existing treatments that work on the whole circulatory system.
Lead researcher, Dr Christoph Hagemeyer, head of the Vascular Biotechnology Laboratory at Baker IDI Heart and Diabetes Institute, said the treatment is safer with fewer side effects.
“Because our drug is targeted,